Results 291 to 300 of about 18,538,974 (359)

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

Dysfunctional high-density lipoprotein: an updated review. [PDF]

Front Cardiovasc Med
Ouyang FW, Chiang HH, Hsu WL, Tsai MH, Huang CY, Remaley AT, Akyol O, Chen CH.   +7 more
europepmc   +1 more source

Plasma proteomic profiles of patients during oral anti‐coagulant treatment with vitamin K antagonists

British Journal of Haematology, EarlyView.
Eleonora Camilleri, Bart J. M. van Vlijmen, Mettine H. A. Bos, Manfred Wuhrer, David R. Goodlett, Christoph H. Borchers, Suzanne C. Cannegieter, Nienke van Rein, Yassene Mohammed   +8 more
wiley   +1 more source

Defective high‐density lipoprotein lipoprotection in type 2 diabetes during acute myocardial infarction is rescued by apolipoprotein M/sphingosine‐1‐phosphate loading

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Mortality of patients with type 2 diabetes (T2D) after acute myocardial infarction (AMI) is tremendous and massively increased compared to non‐T2D individuals. The reasons are unclear. High‐density lipoprotein (HDL) conducts lipoprotection during AMI, leading to improved outcomes.
Jens Vogt, Marcel Benkhoff, Nathalie H. Schröder, Hao Hu, Lisa Dannenberg, Petra Keul, Theresia Sarabhai, Kálmán Benedikt Bódis, Tobias Zeus, Philipp Wollnitzke, Malte Kelm, Amin Polzin, Bodo Levkau   +12 more
wiley   +1 more source

HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients. [PDF]

Lipids Health Dis
Begue F, Veeren B, Rondeau P, Florence AM, Jamard S, Montravers P, Tanaka S, Meilhac O, French COVID Study Group.   +8 more
europepmc   +1 more source

Long‐term effects of a multidomain intervention on cognitive function and metabolic control in older adults with type 2 diabetes and mild cognitive impairment: A 42‐month follow‐up of the J‐MIND‐Diabetes study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study investigated the long‐term effects of a multidomain intervention on cognition and metabolic control in patients with type 2 diabetes and mild cognitive impairment (MCI). Materials and methods Outpatients aged 70–85 years were randomized to an 18‐month multidomain intervention (comprising metabolic/vascular risk management ...
Taiki Sugimoto, Takuya Omura, Atsushi Araki, Chie Haneda, Keiko Honda, Minoru Kishi, Toshimasa Takahashi, Kenji Toyoshima, Suguru Tsuume, Kazuaki Uchida, Hisashi Noma, Ayaka Onoyama, Yoko Yokoyama, Mio Shinozaki, Paul K. Crane, Takashi Sakurai, J‐MIND‐Diabetes Study Group   +16 more
wiley   +1 more source

Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy. [PDF]

Kidney Int Rep
Cunningham MA, Hargett AA, Holloway AK, Hall SD, Craine EP, Maillard N, Rizk DV, Julian BA, Novak J, Renfrow MB.   +9 more
europepmc   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source